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Abstract
Objective—To compare rates of contraception between reproductive-aged cancer survivors and 
women in the general U.S. population. Among survivors, the study examined factors associated 
with use of contraception and emergency contraception.
Methods—This study analyzed enrollment data from an ongoing national prospective cohort 
study on reproductive health after cancer entitled the Fertility Information Research Study. We 
compared current contraceptive use in survivors with that of the general population ascertained by 
the 2006–2010 National Survey for Family Growth. Log-binomial regression models estimated 
relative risks for characteristics associated with use of contraception, World Health Organization 
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tiers I–II (sterilization and hormonal) contraceptive methods, and emergency contraception in 
survivors.
Results—Data from 295 survivors (mean age 31.6 ± 5.7 years, range 20–44 years) enrolled in 
this prospective study (85% response rate) were examined. Age-adjusted rates of using tiers I–II 
contraceptive methods were lower in survivors than the general population (34% [28.8–40.0] 
compared with 53% [51.5–54.5], P<.01). Only 56% of survivors reported receiving family 
planning services (counseling, prescription or procedure related to birth control) since cancer 
diagnosis. In adjusted analysis, receipt of family planning services was associated with both 
increased use of tiers I–II contraceptive methods (relative risk 1.3, 95% confidence interval [CI] 
1.1–1.5) and accessing emergency contraception (relative risk 5.0, 95% CI 1.6–16.3) in survivors.
Conclusion—Lower rates of using Tiers I–II contraceptive methods were found in reproductive-
aged cancer survivors compared to the general population of U.S. women. Exposure to family 
planning services across the cancer care continuum may improve contraception utilization among 
these women.
Clinical Trial Registration—ClinicalTrials.gov, www.clinicaltrials.gov, NCT01843140.
INTRODUCTION
In the United States, there are more than 400,000 reproductive-aged women with a history 
of cancer.1 These cancer survivors have unique family planning needs. While many cancer 
treatments increase risks of infertility and premature ovarian aging, most survivors retain 
ovarian function and potential fertility after cancer treatment.2-5 Many survivors also seek to 
attain social and cancer-related milestones prior to pregnancy.6 Therefore, effective 
contraception is needed until pregnancy is desired.
While qualitative studies indicate that safe and reliable contraception is a key concern for 
survivors, awareness of contraceptive options is limited, and contraception rates are low.7-10 
Survivors can underestimate their risk for pregnancy, one potential outcome of which is 
unintended pregnancy.9,10 Supporting this finding are several studies that suggest increased 
rates of therapeutic abortion in this population.11,12 However, it is unclear if these 
concerning contraceptive practices deviate from those of the general U.S. population and 
what exposures drive these behaviors. Additionally, unintended pregnancy and emergency 
contraception are not described in survivors.13
The primary objective was to compare contraception rates between reproductive-aged 
cancer survivors and women in the general U.S. population. We hypothesized that survivors 
would have lower rates of contraception compared to the general population, as reported by 
the National Survey of Family Growth, the population-based U.S. fertility survey.14,15 
Second, the study examined factors associated with survivors’ use of any contraception, 
more effective contraceptive methods, and emergency contraception.
MATERIALS AND METHODS
This is a analysis of enrollment data from an ongoing national prospective cohort study 
entitled the Fertility Information Research Study (NCT01843140). Participants were 
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recruited through referrals from diverse sources: social media outreach by cancer advocacy 
groups (60%), six university-based fertility preservation programs (26%), FERTLINE—the 
Oncofertility Consortium’s telephone hotline (6%), community outreach, or word of mouth 
(8%).16 Between May 2011 and February 2013, 352 female survivors ages 18–44 years 
were approached; 295 survivors were enrolled from 44 states (85% response rate). The 
institutional review board at University of California, San Diego approved this study.
Eligible survivors provided informed consent to participate and completed annual 
questionnaires by telephone interview or the Internet. These analyses used data from the 
enrollment questionnaire of 289 participants (98% of enrolled) who were ages 20-44 to be 
comparable in age to the general population data reported by the National Survey for Family 
Growth.14,15 The enrollment questionnaire ascertained demographic, cancer, hysterectomy, 
oophorectomy, pregnancy intention, fertility, and pregnancy information.17-19 Current 
contraceptive use, emergency contraception use, and receipt of family planning services 
were assessed using questions derived from the 2006-2010 National Survey for Family 
Growth Cycle.15 (See the Appendix online at http://links.lww.com/xxx.)
Contraceptive practices in survivors were compared to those reported by the National 
Survey for Family Growth, a population-based study conducted by the CDC to provide 
reliable national data on marriage, divorce, contraception, infertility, and the health of 
American women.15 In the 2006-2010 cycle, a nationally representative sample of 12,279 
women ages 15-44 was interviewed using standardized questionnaires (78% response 
rate).20 Weights were used to adjust for different sampling, response and coverage rates to 
generate accurate national estimates.20
Descriptive statistics were calculated as frequencies and percentages, or median and 
interquartile ranges (IQR). The primary comparison was current contraceptive use between 
survivors and the general population. Secondarily, current use of World Health Organization 
(WHO) Tiers I and II contraceptive methods and emergency contraception use after cancer 
diagnosis were examined within survivors.
For current contraceptive use, National Survey for Family Growth methods were used to 
categorize survivors.14 Survivors were categorized by the most effective method for 
preventing pregnancy they reported using.14 Survivors who reported no contraception were 
assigned standardized reasons in the following order: surgically sterile (eg, hysterectomy, 
bilateral oophorectomy), seeking pregnancy, pregnant or postpartum, sexually active and not 
sexually active.14 We further categorized contracepting participants by WHO Tiers, which 
rate methods by effectiveness in preventing pregnancy.21 Tiers I–II included female and 
male sterilization, intrauterine device, pill and other hormonal methods. Tiers III–IV 
included condom, periodic abstinence, withdrawal, and other methods such as cervical 
cap.21
To compare age-adjusted rates of contraception between survivors and the general 
population, sampling weights were used and the survivor population was age-standardized 
using the general population as the standard.14 For the general population, contraception 
rates are calculated from the entire population, including women who are surgically sterile, 
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pregnant or postpartum, seeking pregnancy, and not sexually active.14 Accordingly, survivor 
contraception rates were also estimated including the entire population of survivors. SAS 
PROC SURVEYFREQ was used to estimate proportions and 95% confidence intervals and 
p-values for comparisons between populations.
Secondarily, within the survivor population, log-binomial regression models estimated 
relative risks (RR) for characteristics associated with current contraception use and 
secondary outcomes.22,23 For current contraceptive use and use of Tiers I–II methods, the 
analyses excluded survivors who were not at risk of unintended pregnancy, i.e. survivors 
who are seeking pregnancy, pregnant or postpartum, surgically sterile or not seeking 
pregnancy. For emergency contraception use after cancer diagnosis, only surgically sterile 
survivors were excluded, because sexual activity, attempting pregnancy, and pregnancy or 
postpartum states can change over time since cancer diagnosis. Variables associated with 
outcomes at p<0.05 in bivariable analyses were included in final adjusted models. Statistical 
significance was set at p<0.05. All analyses were conducted using SAS software v9.3 (Cary, 
NC).
RESULTS
Two hundred eight-nine survivors (98%) were included in this analysis after excluding for 
age younger than 20 (n=3) and missing contraception data (n=3) (Table 1). Mean age 
(standard deviation) at enrollment was 31.6 (5.7) years. Median time since cancer diagnosis 
(interquartile range) was 2.4 (1.1-5.1) years. Most survivors were white (79%), college 
graduates (85%), and in partnered relationships (58%). The most common cancer types were 
breast cancer (32%), lymphoma (25%), and gynecologic (cervix, uterus, ovary) (10%). 
Eighty percent underwent chemotherapy, while 63% underwent surgery and 48% underwent 
radiation. In this cohort, 56% reported receiving family planning services since cancer 
diagnosis, and 50% reported receiving them in the past 12 months. Twenty-nine participants 
(10%) reported emergency contraception use. Among 31 participants with a pregnancy after 
cancer diagnosis, 5 reported an unintended pregnancy, with 2 resulting from contraceptive 
failure. Three participants with unintended pregnancies underwent pregnancy termination.
Figure 1 and Table 2 depict current contraceptive use in survivors and compare rates 
between survivors and the general population. Survivors were less likely to use a 
contraceptive method than women in the general population (57% vs. 69%, p<0.01). 
Moreover, survivors were less likely to use Tiers I–II methods compared to the general 
population (34% vs. 53%, p<0.01). Among those not using contraception, survivors were 
more likely to be surgically sterile for non-contraceptive indications (8% survivors vs. 0.4% 
general population) and less likely to be pregnant or postpartum (0.4% survivors vs. 5% 
general population). The proportion of women who were sexually active but did not report 
other reasons for non-contraception (surgical sterility, pregnant or postpartum, seeking 
pregnancy) was not different between survivors (10%) and the general population (8%).
Several age-specific differences were observed between survivors and the general 
population (Figure 2). Lower contraception rates were seen in 30-34 and 35-39 years old 
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survivors compared to the general population. Rates of using Tiers I–II contraceptive 
methods were also significantly lower in survivors ages 30 and older.
Sensitivity analyses were performed in comparisons of the survivor and general populations. 
Since non-contraceptive surgical sterility was substantially higher in survivors, we excluded 
these women from both populations without substantively different results from the main 
analysis (Table 3). Restricting analyses to those at risk of unintended pregnancy (excluding 
sterility for non-contraceptive indications, pregnant or postpartum, seeking pregnancy, not 
sexually active), survivors still had lower contraception rates than the general population 
(84% vs. 90%, p=0.009), as well as lower rates of using Tiers I–II methods compared to the 
general population (51% vs. 69%, p<0.001).
One hundred eighty-four survivors (64%) were at risk of unintended pregnancy after 
excluding those not sexually active, seeking pregnancy, pregnant or postpartum, or 
surgically sterile from non-contraceptive indications. Among those at risk of unintended 
pregnancy, 154 (84%) reported use of contraception; 94 (51%) used Tiers I–II methods. 
Compared to users of Tiers III–IV methods, survivors who used Tiers I–II methods were 
more likely to have received family planning services (Table 4). Survivors who used Tiers 
I–II methods were also younger, further out from their cancer diagnosis, more likely to be 
obese, and less likely to be partnered or have breast cancer. In adjusted analyses, only 
receipt of family planning services in the past 12 months remained significantly associated 
with use of Tiers I–II methods (RR 1.3, 95%CI 1.1-1.5).
Thirty (16%) survivors who were at risk of unintended pregnancy reported no current 
contraceptive use. In unadjusted analyses, no contraceptive use was associated with older 
age (≥31 vs. <31, RR 2.3, 95%CI 1.1-4.7) and partnered status (RR 3.6, 95%CI 1.3-10.0), 
and inversely associated with receipt of family planning services (RR 0.4, 95%CI 0.2-0.8). 
In adjusted analyses, only partnered status was associated with a higher rate of non-
contraception (RR 3.0, 95%CI 1.1-8.3), while age (RR 1.4, 95%CI 0.7-3.1) and family 
planning services (RR 0.6, 95%CI 0.3-1.1) were attenuated.
Emergency contraception use after cancer diagnosis was examined in 263 survivors, 
excluding 26 who were surgically sterile from non-contraceptive indications. Twenty-nine 
participants (11%) reported using emergency contraception after cancer diagnosis. In 
unadjusted analyses, receipt of family planning services was associated with higher 
emergency contraception use (RR 6.5, 95%CI 2.0-21.0). Additionally, emergency 
contraception use was associated with younger age (<31 vs. ≥31, RR 3.6, 95%CI 1.6-8.1), 
non-breast cancer diagnosis (RR 3.0, 95%CI 1.1-8.5), and longer time since cancer 
diagnosis (≥2 years vs. <2 years, RR 3.5, 95%CI 1.4-9.0). In adjusted models (Table 5), only 
younger age and receipt of family planning services was significantly associated with higher 
emergency contraception use.
DISCUSSION
This study showed lower rates of contraception in reproductive-aged cancer survivors than 
in women in the general U.S. population. Survivors also used less reliable methods, 
Dominick et al. Page 5













incurring risks of unintended pregnancy. Exposure to family planning services in survivors 
may improve contraception utilization, as receipt of family planning services in cancer 
survivorship was significantly related to utilization of more effective forms of contraception 
and accessing emergency contraception.
Among survivors, 57% reported current contraception, consistent with recent reports.7,8 
Low contraception rates among survivors motivated this study to compare contraceptive 
practices with the general population and determine factors related to the behavior. The 
lower contraception rate in survivors compared to the general population may be partially 
explained by more non-contraceptive sterility among survivors. However, sensitivity 
analyses excluding these women, women not at risk of unintended pregnancy, or breast 
cancer survivors (data not shown) all demonstrated significantly lower contraception rates in 
survivors.
Moreover, lower utilization of Tiers I–II methods was observed in survivors compared to the 
general population, which is concerning as rates of unintended pregnancy are significantly 
higher with Tiers III–IV methods such as condoms compared with Tiers I–II methods.24 
One explanation may be concern about hormonal exposure in women with estrogen-
sensitive tumors or hypercoagulable states.13 Accordingly, we found that those using Tiers 
III–IV methods were more likely to have breast cancer and be within 2 years of diagnosis 
compared to Tiers I–II users. Lower utilization of Tiers I–II methods was also attributable to 
low uptake of long-acting reversible contraception (LARC), despite that copper IUDs are 
recommended for women with estrogen-sensitive tumors.13 To improve LARC uptake, 
increased access to information and healthcare providers knowledgeable on contraceptive 
effectiveness and safety are needed.
Among survivors, receipt of family planning services increased use of Tiers I–II 
contraceptive methods by twofold and emergency contraception by fivefold, suggesting 
receipt of family planning services may improve contraception care. This finding is 
consistent with Maslow et al, who found a six-fold increased odds of using Tiers I–II 
methods in survivors who received family planning services.7 In contrast, fertility 
preservation counseling did not affect contraception choices, raising the question of how 
fertility preservation interactions can be optimized for family planning.8 Unfortunately, only 
half of survivors reported receiving contraception-related counseling, testing, prescriptions, 
or procedures since cancer diagnosis, despite likely more access to healthcare than women 
without chronic medical conditions.
Strengths of this study include diversity of cancers represented and data on reproductive 
health outcomes after cancer, allowing us to consider important covariates. By race and 
ethnicity, the study’s survivor population was similar to the general U.S. population of 
reproductive-aged cancer survivors. For example, reproductive-aged U.S. female cancer 
survivors are 76% non-Hispanic white, 9% black, 4% Asian, 14% Hispanic.25 Several 
strategies were undertaken to compare survivors and the general population, including age 
adjustment and use of National Survey for Family Growth methods. Inclusion of all 
survivors, regardless of cancer treatment or menstrual pattern, makes our study more 
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generalizable than prior studies. While limited, this study described prevalence and factors 
related to emergency contraception use in survivors.
Sample size was a limitation. Post-hoc sample size calculations showed 80% power to detect 
a difference in rates of 8% between the survivor and general populations. Our study of 295 
women is among the largest to evaluate contraception after cancer; however, the cohort size 
and limited variability of some characteristics restricted our ability to adjust for potential 
confounding factors other than age, such as race, ethnicity and education. Given the 
sociodemographic characteristics of survivors, they likely represent the upper bound of 
contraception use that might be observed in a more diverse survivor population. The study 
was not designed to compare rates of unintended pregnancy, an important clinical outcome. 
The low unintended pregnancy rate may reflect short time since cancer treatment for ovarian 
recovery of our survivors or different risks of unintended pregnancy after cancer, to be 
answered in future studies. The small numbers of survivors who used emergency 
contraception or were not contracepting while at risk of an unintended pregnancy impacted 
the number of covariates log-binomial models could accommodate, although estimates did 
not appreciably change with logistic models.23 Other study limitations include: self-reported 
study variables, inability to determine causation with the cross-sectional design, and 
generalizability of survivors who enrolled in a study on reproductive health. We lack 
information on religion, insurance coverage, potential ambivalence about unintended 
pregnancy, and other possible reasons for less effective contraceptive choices.
The study provides novel evidence of lower rates of using effective contraceptive methods 
in reproductive-aged cancer survivors compared to the general U.S. population. Increased 
access to family planning services may improve survivorship care and prevent unintended 
pregnancy in this vulnerable population.
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Contraceptive methods used by reproductive-aged cancer survivors (n=154), categorized by 
the most effective method.
Dominick et al. Page 10













Dominick et al. Page 11














Comparison of contraceptive practices between reproductive-aged cancer survivors (shown 
in blue) and women in the general U.S. population, as assessed by the National Survey of 
Family Growth (shown in white): use of contraception (A), use of World Health 
Organization (WHO) tiers I-II methods (B), use of WHO tiers III-IV methods (C), surgically 
sterile (D), pregnant or postpartum (E), seeking pregnancy (F), not sexually active (G), 
sexually active (H). The total number of survivors by age group is as follows: aged 20–24 
years (n=38), aged 25– 29 years (n=81), aged 30– 34 years (n=83), aged 35– 39 years 
(n=69), and aged 40–44 years (n=18). *Nonoverlapping 95% confidence intervals of the 
proportions in the survivor and general populations.
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Table 1
Descriptive characteristics of reproductive-aged female cancer survivors and women in the general U.S. 
population




 20 to 24 38 (13.2) 10,365 (20.2)
 25 to 29 81 (28.0) 10,535 (20.6)
 30 to 34 83 (28.7) 9,188 (18.0)
 35 to 39 69 (23.9) 10,538 (20.6)
 40 to 44 18 (6.2) 10,539 (20.6)
Race
 White 227 (78.8) 37,872 (73.9)
 Black 9 (3.1) 7,767 (15.1)
 Other 52 (18.1) 5,638 (11.0)
Ethnicity
 Hispanic 27 (9.4) 8,570 (16.7)
 Non-Hispanic 261 (90.6) 42,707 (83.3)
Body Mass Index, kg/m2
 < 25 162 (56.1) 22,188 (43.6)
 25 to 29.9 64 (22.1) 12,497 (24.5)
 ≥ 30 63 (21.8) 16,245 (31.9)
Education: College Graduate 239 (84.5) 15,118 (29.5)
Income
 ≤ $50,000 95 (32.9) 29,878 (58.3)
 > $50,000 138 (47.7) 21,399 (41.7)
 Declined to Answer 56 (19.4) --
Current Health Insurance 274 (95.1) --
Reproductive Characteristics
Partnered Relationship Status 167 (57.8) 31,900 (62.2)
Live Birth 65 (22.5) 33,654 (65.6)
Ever Been Pregnant 103 (35.6) 37,184 (72.5)
Desire to Have a Baby in the Future 235 (81.3) 27,481 (53.6)
Received Family Planning Services
 In the Past 12 Months 145 (50.4) 20,710 (40.4)
 Since Cancer Diagnosis 162 (56.3) --
Ever Use of Emergency Contraception since Cancer Diagnosis 29 (10.0) --
Unintended Pregnancy after Cancer Diagnosis 5 (1.7) --
Cancer Characteristics
Cancer Diagnosis
 Breast 91 (31.5) --
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Participant Characteristics Cancer Survivors n=289 n (%) General Population n=51,277* n (%)
 Lymphoma 71 (24.5) --
 Gynecologic (cervix/uterus/ovary) 28 (9.7) --
 Blood/leukemia 22 (7.6) --
 Thyroid 15 (5.2) --
 Other 62 (21.5) --
Cancer Stage
 I 59 (20.4) --
 II 86 (29.8) --
 III 56 (19.4) --
 IV 23 (7.9) --
 Unknown 65 (22.5) --
Cancer Treatment
 Surgery 183 (63.3) --
 Chemotherapy 230 (79.6) --
 Radiation Therapy 140 (48.4) --
 Bone Marrow or Stem Cell Transplant 16 (5.5) --
Time since Cancer Diagnosis, years
 Median (IQR) 2.4 (1.1 - 5.1) --
 < 2 122 (42.4) --
  ≥ 2 166 (57.6) --
Comorbid Medical Conditions†
 0 96 (33.2) --
 1 or more 193 (66.8) --
Abbreviation: IQR, interquartile range
*
General population as reported by the National Survey for Family Growth 2006-2010 cycle.15 Numbers are expressed in thousands and are based 
on applying sampling weights to 9995 respondents aged 20-44 years. Cancer-related variables were not collected by the survey.
Note: Due to missing data, some variables do not add up to 289 for cancer survivors or 51,276,864 for women in the general population.
†
Comorbid medical conditions included lung disease, hypertension, diabetes, overweight/obese, thyroid disorders, mood disorders, eating 
disorders, rheumatologic diseases, inflammatory bowel disease, neurologic disorders.
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Table 2
Comparison of age-adjusted rates of contraceptive practices between the cancer survivor and general 
populations
Contraceptive Status and Method Cancer Survivors n=289 General Population n=51,277*
P valuePercent (95% CI)
Using contraception 57.4 (51.5 - 63.2) 68.6 (67.3 - 70.0) <0.01
Contraception methods <0.01
WHO Tiers I/II† 34.2 (28.8 - 40.0) 53.0 (51.5 - 54.5)
 Female Sterilization† 0.3 (0.0 - 1.9) 19.9 (18.7 - 21.1)
 Male Sterilization 4.2 (2.2 - 7.1) 7.5 (6.7 - 8.4)
 Intrauterine Device 5.9 (3.5 - 9.3) 4.0 (3.5 - 4.6)
 Implant, Lunelle or Patch 0.3 (0.0 - 1.9) 0.9 (0.6 - 1.1)
 Pill 20.8 (16.2 - 25.9) 17.2 (16.1 - 18.4)
 3-month Injectable (Depo-Provera) 0.3 (0.0 - 1.9) 2.0 (1.7 - 2.3)
 Contraceptive Ring 2.4 (1.0 - 4.9) 1.5 (1.1 - 1.8)
WHO Tiers III/IV† 23.2 (18.4 - 28.5) 15.6 (14.5 - 16.6)
 Condom† 20.4 (15.9 - 25.5) 11.0 (10.1 - 11.9)
 Periodic Abstinence (family planning/calendar rhythm) 1.7 (0.6 - 4.0) 0.8 (0.6 - 1.1)
 Withdrawal† 0.7 (0.1 - 2.5) 3.4 (2.9 - 4.0)
 Other Methods 0.0 (0.0 - 1.3) 0.3 (0.1 - 0.5)
Not using contraception <0.01
Surgically Sterile (female) † 8.3 (5.4 - 12.1) 0.4 (0.2 - 0.7)
Nonsurgically Sterile‡(female or male) -- 1.9 (1.5 - 2.3)
Pregnant or Postpartum† 0.4 (0.0 - 1.9) 4.7 (4.1 - 5.2)
Seeking Pregnancy 9.0 (6.0 - 12.9) 5.4 (4.7 - 6.1)
Not Sexually Active 14.9 (11.0 - 19.5) 11.0 (10.1 - 11.9)
Sexually Active 10.0 (6.8 - 14.1) 7.9 (7.2 - 8.7)
Abbreviations: WHO, World Health Organization
*
General population as reported by the National Survey for Family Growth 2006-2010 cycle.15 Numbers are expressed in thousands and are based 
on applying sampling weights to 9995 respondents aged 20-44 years.
†
denotes non-overlapping 95% CIs of the proportions in the survivor and general populations.
‡
For survivors, nonsurgically sterile is unknown and not included in the above table.
Notes: Overall comparisons performed using SAS PROC SURVEYFREQ with age-group weights to standardize for age. P-values from chi-square 
tests of homogeneity.
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Table 3
Comparison of age-adjusted rates of contraceptive practices between the cancer survivor and general 
populations, excluding participants who are surgically sterile for non-contraceptive indications
Contraceptive Status and Method Cancer Survivors =265 General Population n=51,277*
P valuePercent (95% CI)
Using contraception 60.8 (54.9 - 66.7) 69.0 (67.6 - 70.3) <0.01
Contraception methods <0.01
WHO Tiers I/II† 36.7 (30.8 - 42.6) 53.2 (51.8 - 54.7)
 Female Sterilization† 0.7 (0.0 - 1.6) 19.9 (18.7 - 21.1)
 Male Sterilization† 1.9 (0.2 – 3.6) 7.5 (6.7 - 8.4)
 Intrauterine Device 7.9 (4.6 - 11.1) 4.0 (3.5 - 4.6)
 Implant, Lunelle or Patch 0.4 (0.0 - 1.2) 0.9 (0.6 - 1.1)
 Pill 22.0 (17.0 - 27.1) 17.4 (16.2 - 18.5)
 3-month Injectable (Depo-Provera) 0.4 (0.0 - 1.2) 2.0 (1.7 - 2.3)
 Contraceptive Ring 3.5 (1.3 - 5.8) 1.5 (1.1 - 1.8)
WHO Tiers III/IV† 24.1 (18.9 - 29.3) 15.7 (14.6 - 16.7)
 Condom† 21.8 (16.8 - 26.9) 11.1 (10.2 - 12.0)
 Periodic Abstinence (family planning/calendar rhythm) 1.2 (0.0 - 2.5) 0.8 (0.6 - 1.1)
 Withdrawal† 1.2 (0.0 - 2.5) 3.5 (2.9 - 4.0)
 Other Methods 0.0 (0.0 – 0.0) 0.3 (0.1 - 0.5)
Not using contraception <0.01
Nonsurgically Sterile‡(female or male) -- 1.9 (1.5 - 2.3)
Pregnant or Postpartum† 0.3 (0.0 - 1.0) 4.7 (4.1 - 5.3)
Seeking Pregnancy 9.7 (6.1 - 13.3) 5.4 (4.8 - 6.1)
Not Sexually Active 17.6 (13.0 - 22.2) 11.1 (10.2 – 12.0)
Sexually Active 11.4 (7.5 – 15.2) 7.9 (7.2 - 8.7)
Abbreviations: WHO, World Health Organization
Notes: Overall comparisons performed using SAS PROC SURVEYFREQ with age-group weights to standardize for age. P-values from chi-square 
tests of homogeneity.
*
General population as reported by the National Survey for Family Growth 2006-2010 cycle15. Numbers are expressed in thousands and are based 
on applying sampling weights to 9995 respondents aged 20-44 years.
†
denotes non-overlapping 95% CIs of the proportions in the survivor and general populations.
‡
For survivors, nonsurgically sterile is unknown and not included in the above table.











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Obstet Gynecol. Author manuscript; available in PMC 2016 September 01.
